EVGN
Evogene
NASDAQ: EVGN · HEALTHCARE · BIOTECHNOLOGY
$0.78
+2.88% today
Updated 2026-04-30
Market cap
$9.54M
P/E ratio
—
P/S ratio
2.48x
EPS (TTM)
$-1.70
Dividend yield
—
52W range
$1 – $2
Volume
0.1M
Evogene (EVGN) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $2.13M | $-1.89M | $-5.27M | $-8.89M | $-12.41M | $-11.69M | $-15.93M | $-15.16M | $-17.36M | $-19.51M | $-24.84M | $-23.68M | $-21.58M | $-19.70M | $-13.50M |
| Capital expenditures | $3.76M | $2.96M | $1.61M | $3.56M | $2.00M | $808000.00 | $590000.00 | $374000.00 | $900000.00 | $682000.00 | $724000.00 | $1.17M | $785000.00 | $626000.00 | $135000.00 |
| Depreciation | $1.42M | $1.83M | $2.04M | $2.25M | $2.43M | $2.28M | $2.15M | $2.02M | $2.77M | $2.73M | $2.23M | $2.58M | $2.61M | $2.50M | — |
| Stock-based comp | $2.13M | $1.17M | $2.73M | $3.23M | $4.37M | $2.94M | $2.24M | $1.73M | $1.58M | $4.10M | $2.61M | $1.19M | $1.88M | $1.79M | $654000.00 |
| Free cash flow | $-1.63M | $-4.85M | $-6.88M | $-12.46M | $-14.41M | $-12.50M | $-16.52M | $-15.54M | $-18.26M | $-20.20M | $-25.56M | $-24.85M | $-22.36M | $-20.33M | $-13.64M |
| Investing cash flow | $-30.58M | $18.48M | $-2.90M | $-84.03M | $17.39M | $4.03M | $15.24M | $17.35M | $37.14M | $9.41M | $-20.44M | $13.27M | $-4.54M | $9.62M | — |
| Financing cash flow | $25.58M | $1.11M | $79.41M | $2.67M | $45000.00 | $655000.00 | $814000.00 | $297000.00 | $9.00M | $20.37M | $30.28M | $9.34M | $18.15M | $4.66M | — |
| Dividends paid | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |